Biocon Ltd, a leading biotechnology company, is all set to launch its derma and skincare portfolio as it seeks to expand the range of therapeutic segments in which it offers products. “The first product will be an ointment with immunosuppressants. We will have a tacrolimus ointment to begin with, but we will eventually offer a large portfolio. This will be hopefully a frontrunner to launch our psoriasis treatment after it successfully completes all trials,” says Kiran Mazumdar Shaw, Chairman and Managing Director, Biocon India. Biocon has a significant presence in four therapeutic segments — diabetology, oncology, nephrology and cardiology.